<PAGE>
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities and Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
November 6, 1996
NITINOL MEDICAL TECHNOLOGIES, INC.
- --------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in its Charter)
<TABLE>
<CAPTION>
<S> <C> <C>
Delaware 0-21001 95-4090463
- ------------------ -------- ----------
(State or other (Commission File (IRS Employer
jurisdiction of Number) Identification
incorporation) No.)
</TABLE>
27 Wormwood Street
Boston, Massachusetts 02210
----------------------------------------------
(Address of principal executive offices)
Registrant's Telephone Number, including
area code: (617) 737-0930
------------------------------------------------------------------
(Former Address, if changed since last report)
- --------------------------------------------------------------------------------
<PAGE>
Item 5. Other Events.
------------
On November 6, 1996, the Bard Radiology Division of C.R. Bard, Inc.
("Bard") exercised its option to renew the term of that certain Distribution
Agreement, by and between Bard and Nitinol Medical Technologies, Inc., dated May
19, 1992, as amended on February 1, 1993 and October 1, 1995, for a period of
five years commencing on May 19, 1997.
-2-
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
November 22, 1996
NITINOL MEDICAL TECHNOLOGIES, INC.
By: /s/ Theodore I. Pincus
----------------------------
Theodore I. Pincus,
Chief Financial Officer
-3-
